Camberlogo1 (Camberlogo1)
Sildenafil For Suspension
Product Images NDC 31722-136
23 FDA label images from Camber Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 31722-136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Camberlogo2 (Camberlogo2)
Sildenafiloscontcarton (Sildenafiloscontcarton)
Packaging label for Sildenafil for Oral Suspension 10 mg/mL by Camber Pharmaceuticals, Inc. It is a 112 mL bottle after reconstitution, grape flavored, indicated for oral use only. Directions and storage instructions are included, with emphasis on shaking well before each use. The label also states Rx only and includes manufacturer and batch coding areas.*
Sildenafilosfig1 (Sildenafilosfig1)
An illustration showing a graduated cylinder marked in milliliters on the left, and a bottle partially filled with liquid labeled as Figure 1 in the center. To the right, a graduated oral syringe is shown with dosing marks and indicated as a single unit (x1). The diagram appears to demonstrate measuring and administering liquid suspension.*
Sildenafilosfig10 (Sildenafilosfig10)
A forest plot chart depicting the placebo-corrected change in 6-minute walk distance, measured in meters, for different patient subgroups treated with Sildenafil 20 mg TID versus placebo. The subgroups are defined by baseline walk distance, etiology of pulmonary arterial hypertension (PAH), PH criteria for functional capacity and therapeutic class, gender, age, mean pulmonary artery pressure (PAP), and pulmonary vascular resistance index (PVRI). Each subgroup shows mean differences with horizontal confidence intervals for Sildenafil compared to placebo.*
Sildenafilosfig11 (Sildenafilosfig11)
A line graph comparing the percentage of subjects without a clinically worsening event over time between Sildenafil and Placebo groups. The x-axis represents days from randomization (0 to 112), and the y-axis shows the percentage without worsening (0% to 100%). The Sildenafil group consistently shows a higher percentage without worsening compared to the Placebo group over the duration of the study.*
Sildenafilosfig12 (Sildenafilosfig12)
A line graph showing mean change from baseline (in meters) over a 12-week study period for Sildenafil oral suspension at doses 1 mg TID, 5 mg TID, and 20 mg TID. The graph includes standard error bars for each dose at weeks 4, 8, and 12, illustrating changes in measured distance relative to baseline.*
Sildenafilosfig2 (Sildenafilosfig2)
An instructional diagram showing three steps: pressing down and turning a bottle cap to open, shaking the bottle vertically to mix the suspension, and a stopwatch indicating timing, likely guidance for preparation or administration timing for Sildenafil Powder for Suspension 10 mg/mL by Camber Pharmaceuticals, Inc.*
Sildenafilosfig3 (Sildenafilosfig3)
An instructional diagram showing a medicine bottle with a screw cap and two graduated measuring devices, a graduated cylinder labeled as Figure 3 and a syringe marked x1, used for measuring liquid medication accurately.*
Sildenafilosfig4 (Sildenafilosfig4)
An instructional diagram showing three steps for preparing an oral suspension. The first step shows a hand twisting the cap off a bottle. The second step shows the bottle being shaken up and down. The third step depicts a timer set for one minute, indicating the shaking duration.*
Sildenafilosfig5 (Sildenafilosfig5)
Illustration showing the steps for opening a bottle of Sildenafil Powder for Suspension, 10 mg/mL. The left side depicts a hand removing a cap from the bottle, and the right side shows the cap being twisted or pushed to open the bottle.*
Sildenafilosfig6 (Sildenafilosfig6)
A line graph depicting estimated cumulative mortality rates (%) over time in years for three dosing groups labeled High Dose, Medium Dose, and Low Dose. The x-axis represents time in years from 0 to 5, and the y-axis shows mortality rates from 0 to 25%. The graph includes the number at risk for each group at various time points along the top.*
Sildenafilosfig7 (Sildenafilosfig7)
A chart illustrating the fold change and 90% confidence intervals of various interacting drugs relative to Sildenafil alone, with recommendations for dose adjustments. The graph compares AUC and Cmax values for drugs including Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral contraceptives, Ritonavir, and Saquinavir, highlighting whether dose adjustments are needed or coadministration is advised against.*
Sildenafilosfig8 (Sildenafilosfig8)
A forest plot displaying fold change and 90% confidence intervals comparing pharmacokinetic variables of Sildenafil when administered with various interacting drugs. The graph shows fold change relative to the interacting drug alone on the x-axis, with a vertical line at 1 indicating no change. Drugs listed include Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin (three doses), Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide, each with associated recommendations, mostly indicating no dose adjustment.*
Sildenafilosfig9 (Sildenafilosfig9)
A line graph depicting changes from baseline in meters over weeks 4, 8, and 12 of a study measuring walking distance. The graph compares four groups: Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, with error bars indicating variability. The x-axis represents the week of study, and the y-axis represents the change from baseline in meters.*
Sildenafilosfiga (Sildenafilosfiga)
An instructional diagram showing components of a Sildenafil for oral suspension package. It labels a bottle of Sildenafil powder for suspension with a cap and syringe adaptor, alongside a syringe with labeled parts: tip, barrel with volume markings (2 mL and 5 mL), and plunger. The diagram aids in understanding the preparation or administration process.*
Sildenafilosfigb (Sildenafilosfigb)
An instructional diagram illustrating how to shake a suspension bottle by moving it up and down with twisting motion, a stopwatch showing timing for 15 seconds, and a hand removing or twisting the bottle cap, likely demonstrating steps for preparing or administering an oral suspension.*
Sildenafilosfigc (Sildenafilosfigc)
An instructional diagram showing a hand holding a bottle with a suspension inside while another hand inserts a measuring syringe into the bottle's neck. An arrow indicates the downward movement of the syringe into the bottle, illustrating the step to draw suspension liquid for oral use.*
Sildenafilosfigd (Sildenafilosfigd)
An instructional illustration showing how to prepare a suspension by drawing liquid from a bottle using a syringe. The image depicts hands holding the bottle and syringe, with a downward arrow indicating the action of pulling the syringe plunger to draw the medication.*
Sildenafilosfige (Sildenafilosfige)
Illustration showing a syringe inserted into the top of a bottle with an arrow pointing upward, indicating removal or drawing of liquid. This likely relates to use or preparation instructions for Sildenafil Powder for Suspension, 10 mg/mL by Camber Pharmaceuticals.*
Sildenafilosfigf (Sildenafilosfigf)
An instructional illustration labeled Figure F showing the administration of medication using a syringe-like device placed inside the mouth against the cheek, indicating an oral route for administering the suspension.*
Sildenafilosfigg (Sildenafilosfigg)
Illustration labeled Figure G showing a water faucet and two test tubes or small cylindrical containers positioned underneath the faucet spout, likely depicting a procedure involving water or liquid flow into the containers.*
Sildenafilosstructure (Sildenafilosstructure)
Chemical structure diagram of Sildenafil, showing the molecular framework with labeled functional groups and rings consistent with the active ingredient Sildenafil Powder.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
